It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chemotherapy often induces oral ulcerative mucositis (OUM) in patients with cancer, characterized by severe painful inflammation. Mouth-washing with the Japanese herbal medicine hangeshashinto (HST) ameliorates chemotherapy-induced OUM in patients with colorectal cancer. Previously, we demonstrated that HST decreased interleukin 1β-induced prostaglandin E2 production in human oral keratinocytes (HOKs) and OUM-induced mechanical or spontaneous pain in rats. However, HST effects on tissue repair functions in HOKs remain unclear. Here, we examined the effects of HST on scratch-induced wound healing in vitro and in vivo. In vitro, HST enhanced wound healing mainly through scratch-induced HOK migration. Screening of the seven constituent medicinal herbs and their major components revealed that Scutellaria root, processed ginger, and Glycyrrhiza components mainly induced the scratch-induced HOK migration. Pharmacokinetic analyses indicated that the active ingredient concentrations in rat plasma following oral HST administration were below the effective doses for HOK migration, suggesting direct effects of HST in OUM. Mitogen-activated protein kinase and C-X-C chemokine receptor 4 inhibitors significantly suppressed HST-induced HOK migration. Moreover, HST enhanced tissue repair in our OUM rat model. Thus, HST likely enhanced OUM tissue repair through oral keratinocyte migration upon MAPK and CXCR4 activation and may be useful in patients with cancer-associated OUM.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 National Cancer Center Research Institute, Division of Cancer Pathophysiology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385)
2 National Cancer Center Research Institute, Division of Cancer Pathophysiology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385); Tokyo University of Science, Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
3 Kyushu Dental University, Division of Physiology, Fukuoka, Japan (GRID:grid.411238.d) (ISNI:0000 0004 0372 2359)
4 Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan (GRID:grid.510132.4)
5 National Cancer Center Research Institute, Division of Cancer Pathophysiology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385); Kitasato University, Department of Medicinal Chemistry, School of Pharmacy, Tokyo, Japan (GRID:grid.410786.c) (ISNI:0000 0000 9206 2938)
6 Kitasato University, Department of Medicinal Chemistry, School of Pharmacy, Tokyo, Japan (GRID:grid.410786.c) (ISNI:0000 0000 9206 2938)
7 Tokyo University of Science, Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861); Tokyo University of Science, Translational Research Center, Research Institute of Science and Technology, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861)
8 Sapporo Higashi Tokushukai Hospital, Center for Clinical and Biomedical Research, Sapporo, Japan (GRID:grid.490419.1) (ISNI:0000 0004 1763 9791)
9 National Cancer Center Research Institute, Division of Cancer Pathophysiology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385); Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Division of Supportive Care Research, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385); Palliative and Psychosocial Care, National Cancer Center Hospital, Innovation Center for Supportive, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385)